Cardio Metabolic Health Congress – Official Blog

Another GLP-1 Agonist, Semaglutide, Shows Cardiovascular Benefit in CV Outcomes Trial SUSTAIN 6

The GLP-1 agonist semaglutide is the latest diabetes therapy to show cardiovascular benefit in a CV outcomes trial, demonstrating a reduction in the risk of major adverse cardiovascular events compared with usual care.

SUSTAIN 6 included 3,297 patients with type 2 diabetes on a standard diabetes care regimen randomized to once-weekly semaglutide or placebo for 2.1 years. Among those who received semaglutide, the rate of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke was lowered to 6.6% compared with 8.9% in the placebo group receiving usual care. Researcher Dr. Steven Marso of HCA Midwest Health Research Medical Center in Kansas City, MO, commented that this lower risk was largely driven by a significant (39%) decrease in the rate of nonfatal stroke and a nonsignificant (26%) decrease in nonfatal myocardial infarction. No significant difference in the rate of cardiovascular death was observed. Read more

PCSK9 Inhibitors: 1 Year After Approval

One year after FDA approval, are PCSK9 inhibitors living up to expectations?

It’s been about 1 year since the two currently available PCSK9 inhibitors, evolocumab and alirocumab, received US FDA approval. (Bococizumab is still completing phase 3 studies.) Uptake, as most in the healthcare community know, has been slow, largely due to the cost associated with the two therapies.

The US FDA recently approved a monthly single-dose administration option for evolocumab. The system consists of a hands-free device which is designed to provide 420 mg of evolocumab in a single dose and allows patients the freedom of being able to continue with moderate physical activity such as walking, reaching, and bending. The cost is expected to remain similar to twice weekly dosing, and given how new it is, it remains to be seen what kind of impact on clinical practice it will have. Read more